Mesothelioma Cancer Research News

Mesothelioma in the News: Mesothelioma Lawsuits

Mesothelioma cancer research news encompasses the latest developments, breakthroughs, and studies related to this rare and aggressive form of cancer. Researchers and scientists worldwide are dedicated to finding better treatment options, improving early detection methods, and ultimately, searching for a cure. These ongoing efforts bring hope to patients and their families, as new discoveries may lead to more effective therapies, extended survival rates, and an improved quality of life for those affected by mesothelioma. Staying informed about the latest research is vital for both patients and medical professionals as they continue to fight against this challenging disease.

Study highlights YB-1 targeting as novel treatment approach for pleural mesothelioma

Download PDF Copy

Reviewed by Lily Ramsey, LLMOct 11 2023

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study led by Karin Schelch and Michael Grusch from MedUni Vienna identified the oncoprotein YB-1 as an attractive therapeutic target in PM and demonstrates that indirect targeting of YB-1 is a promising approach to enhance sensitivity to chemo- and radiotherapy. The study results were published in the medical journal “Cancer Letters”.

The study follows on from findings published earlier this year by the research group led by Michael Grusch (Center for Cancer Research at MedUni Vienna and Comprehensive Cancer Center at MedUni Vienna and University Hospital Vienna), according to which the oncoprotein YB-1 is involved in regulating multiple traits of pleural mesothelioma (PM) such as cell growth, cell death and migration. The current study proves its relevance also in drug response. Accordingly, YB-1 knockdown via siRNA resulted in significantly reduced tumor growth and furthermore enhanced the sensitivity to cisplatin and radiation.

Reaching the target

Histone deaceylase inhibitors (HDACi) have already been shown in trials to be effective in fighting tumor cells of different types. Since there are no pharmaceutical YB-1 inhibitors available, indirect targeting of YB-1 was achieved by the HDACi entinostat which also inhibits YB-1 deacetylation, thereby modifying its function. “Our findings provide the basis for the development of novel, clinically feasible therapy approaches” says principal investigator Michael Grusch from the Center of Cancer Research and Comprehensive Cancer Center, highlighting the study’s high clinical relevance.

(Click Here to Continue Reading from source)

Can a Breath Test Detect Mesothelioma? It’s Too Soon to Tell

September 15, 2023

Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible, but more research is needed.

The test, which detects volatile organic compounds in exhaled breath, is being evaluated in the MESOBREATH 5 study.

Early results showed that the test has high sensitivity and negative predictive value but low accuracy, specificity, and positive predictive value. These results were presented at the 2023 World Conference on Lung Cancer.

Patients included in this study were required to have a history of substantial occupational asbestos exposure, with a first exposure occurring at least 30 years ago and having at least 15 fiber years. The researchers also included a positive control group of patients with confirmed pleural mesothelioma.

(Click Here to Continue Reading from source)

New Research Sheds Light on How Mesothelioma Develops

by University of Maryland

MAY 10, 2023

The incurable cancer develops on the lining of many internal organs—including the lungs and peritoneum—but its symptoms are often undetectable until about 40 years after initial exposure to asbestos, a common and naturally occurring mineral. This long latency period, as well as cases of mesothelioma in individuals who have no known exposure to asbestos, has made the disease and its origins a longstanding puzzle to doctors and scientists alike.

Now, an interdisciplinary team of researchers from the University of Maryland may have identified an essential piece of the puzzle. In a paper published online in the journal Environmental Research in January 2023, the team suggests that the key to understanding mesothelioma lies in how immune cells “sense” and interact with particles around them.

According to the new study, the shape and size of contaminant particles, like asbestos fibers, significantly influence how the immune system responds after exposure—ultimately impacting health outcomes.

(Click Here to Continue Reading from source)

Cancer discovery: protein promotes inflammation, after asbestos exposure

UH News » Research » Cancer discovery: protein promotes…

September 20, 2023

UH News

Mesothelioma is a very aggressive type of cancer that primarily affects the thin tissue lining of the chest and the abdomen. It leads to approximately 3,200 deaths per year in the U.S. and is often caused by exposure to asbestos.

New public impact research led by the University of Hawaiʻi Cancer Center has discovered that the HMGB1 protein plays a critical role in the development of asbestos-induced mesothelioma. Future research will examine how this protein influences cells at different stages in the disease to prevent or reduce the growth of mesothelioma.

Michele Carbone and Haining Yang

The international research team was led by Haining Yang and Michele Carbone whose previous study discovered the key to increasing the survival rate of mesothelioma could also ultimately be used to treat other types of cancer.

This new research found that following asbestos exposure, HMGB1 is released out of the cells and kick-starts an inflammatory process that, over time, promotes mesothelioma. The study published in the September 18 issue of Proceedings of the National Academy of Sciences of the U.S. aimed to identify the primary cell type responsible for HMGB1 production upon asbestos exposure.

(Click Here to Continue Reading from source)

Pembrolizumab regimen ‘ticks all the efficacy boxes’ for advanced mesothelioma

June 06, 2023

By Drew Amorosi

Fact checked by Mindy Valcarcel

Key takeaways:

The trial met its primary endpoint, showing significant improvement in OS with the pembrolizumab regimen vs. chemotherapy alone.

The pembrolizumab regimen decreased risk for death by 21%.

CHICAGO — The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for adults with advanced malignant pleural mesothelioma, according to results of the randomized phase 3 IND.227/KEYNOTE-483 trial.

The data, presented at ASCO Annual Meeting, showed the pembrolizumab-containing regimen reduced the risk for death by 21% compared with chemotherapy alone.

Adults with advanced malignant pleural mesothelioma who received pembrolizumab in addition to chemotherapy demonstrated significant improvement in OS. Image: Adobe Stock

“It ticks all the efficacy boxes,” Scott A. Laurie, MD, FRCPC, a researcher and thoracic medical oncologist at The Ottawa Hospital and associate professor of medicine in the division of medical oncology at University of Ottawa, told Healio. “This familiar regimen — one oncologists already use routinely in the management of non-small cell lung cancer — should become a new therapeutic option for patients with advanced pleural mesothelioma.”

(Click Here to Continue Reading from source)

Preoperative immunotherapy for mesothelioma shows favorable outcomes

Dipali Pathak

Dec 13, 2022

In a study published recently in the journal Clinical Cancer Research, researchers at Baylor College of Medicine found that treating patients who have resectable malignant pleural mesothelioma, meaning that their tumor can be removed with surgery, with immunotherapy ahead of surgery resulted in favorable clinical outcomes. The study lays the groundwork for neoadjuvant immunotherapy in mesothelioma.

“Mesothelioma is a devastating disease with low survivability,” said Dr. Bryan Burt, professor and chief of the David J. Sugarbaker Division of Thoracic Surgery in the Michael E. DeBakey Department of Surgery at Baylor and senior author of the paper. “Traditionally, this disease has defeated all standard therapies.”

Immune checkpoint inhibitors are drugs that activate the immune system to fight cancer. They have revolutionized the treatment of cancer in general, but only recently have been recognized to have some efficacy in mesothelioma. Recent research on the efficacy of immunotherapy for patients with unresectable mesothelioma showed favorable outcomes, which led Burt and colleagues to study this approach in patients with resectable mesothelioma.

(Click Here to Continue Reading from source)

INBRE Grants Fund Asbestos Exposure Treatment, Embryo Development Research at Idaho State University

May 22, 2023

A pair of grants are kickstarting research at Idaho State University into new ways of treating exposure to a deadly carcinogen and congenital disorders.

Recently, Kinta Serve, associate professor, and Heather Ray, assistant professor, in ISU’s Department of Biological Sciences, were each awarded a Pilot Project grant from the Idaho INBRE Program. Serve will be trying to identify new and earlier ways of treating asbestos exposure. Serve and her students will be looking into how changes in the pleural cavity – the small cavity surrounding the lungs – of mice following exposure to asbestos lead to chronic diseases like mesothelioma and asbestosis.

“Asbestos exposure is an ongoing health risk, especially among people living or working in older buildings that were constructed with asbestos-containing materials,” said Serve. “Many chronic diseases, including asbestos-related diseases, are thought to arise from early changes in immune and cell responses. By studying these immune and cell changes early on – a few weeks after asbestos exposure – we hope to identify new ways of treating or preventing disease.”

(Click Here to Continue Reading from source)

Research Validates IASLC Mesothelioma Staging Model’s Continued Use

Mirage News

12 SEP 2023 12:12 PM AEST

International Association for the Study of Lung Cancer

[Singapore, 10:05 a.m. SGT–September 12, 2023] – A model developed by the International Association for the Study of Lung Cancer in 2009 to help better stage mesothelioma cases performed well, according to an independent analysis presented today at The International Association for the Study of Lung Cancer (IASLC) 2023 Conference in Singapore.

Pleural mesothelioma is a rare but aggressive cancer primarily caused by asbestos exposure and presents complex challenges for effective staging and prognostication. The IASLC took a significant step in 2009 by establishing an international pleural mesothelioma database aimed at enhancing staging accuracy. Subsequently, in 2014, an analysis of data from 1995 to 2009 led to the identification of supplemental prognostic factors. The current study sought to validate and enhance these models using fresh clinical data.

The research, presented by Andrea Wolf, M.D., from The Icahn School of Medicine at Mount Sinai, in New York City, evaluated data from patients entered into the database between 2009 and 2019, constituting a validation cohort of 1,733 individuals. The study introduced additional variables for analysis, with model comparison based on Harrell’s C-index. Two distinct models were evaluated: one incorporating clinicopathological features and treatment (pathologic staging model), and the other encompassing parameters available at patient presentation (basic presentation model).

(Click Here to Continue Reading from source)

RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients

Start-up US biotech company tackling rare diseases presents three case studies in France

August 03, 2023 08:18 AM Eastern Daylight Time

LILLE, France–(BUSINESS WIRE)–RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies. PRX3 is a novel drug target with potential for treating patients with the asbestos related cancer, mesothelioma. It is a key defense against oxidative stress and is located in the mitochondria, the energy generating factories. Inhibiting PRX targets cancer, not normal cells.

RS Oncology presented scientific discovery and case studies from their MITOPE clinical trial at the IMIG conference this year. In this short clip from the symposium, Brian Cunniff, Ph.D., Chief Science Officer for RSO, and Assistant Professor of Pathology and Laboratory Medicine at the University of Vermont Cancer Center, explains the discovery of PRX3 and its role in cancer tumors. The entire video can be watched at

(Click Here to Continue Reading from source)

Extended pleurectomy decortication plus chemotherapy associated with worse outcomes for mesothelioma patients

Download PDF Copy

Reviewed by Lily Ramsey, LLMSep 11 2023

Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed chemotherapy alone, according to research presented today the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

The UK Multicentre Randomised Trial, known as MARS 2, conducted by a team led by Professor Eric Lim from The Royal Brompton Hospital, United Kingdom, investigated the impact of extended pleurectomy decortication combined with chemotherapy compared to chemotherapy alone in patients with mesothelioma.

Mesothelioma, a rare and aggressive cancer primarily linked to asbestos exposure, has prompted exploration into various treatment options, including surgical procedures like pleurectomy decortication. However, despite its common use, the effectiveness of this intervention has never been evaluated in a randomized trial.

The trial, which enrolled 335 participants, randomly assigned 169 patients with resectable mesothelioma to extended pleurectomy decortication and 166 patients to chemotherapy (platinum and pemetrexed) or chemotherapy alone. The researchers followed patients for a median 22.4 months.

(Click Here to Continue Reading from source)

Improved cancer therapies could spring from mesothelioma discovery

UH News

January 22, 2023

A University of Hawaiʻi Cancer Center research team led by Michele Carbone and Haining Yang may have discovered a key to increasing the survival rate of Mesothelioma, one of the deadliest cancers, that could also ultimately be used to treat other types of cancer.

Mesothelioma is a cancer of the membranes covering the lungs, chest and abdomen that is resistant to therapy and has an average survival rate of one to two years. Patients born with only one of the two copies of the BAP1 gene that are normally present in our cells, are affected by the BAP1 Cancer Syndrome and often develop mesothelioma. Surprisingly, most of them respond to therapy and have an average survival rate of seven years, and sometimes are cured.

The researchers found that both copies of the BAP1 gene are required to stabilize HIF1—the protein that allows tumor cells to grow and invade nearby tissues. As observed in patients with only one copy of the BAP1 gene—tumor cells have difficulty growing in the low concentrations of oxygen present in the tumor environment and are more easily killed by therapy. By targeting BAP1 activity, researchers hope to make mesothelioma and other cancers much more susceptible to therapy, which will increase the cancer survival rate. This study was recently published in Proceedings of the National Academy of Sciences of the U.S.

The BAP1 Cancer Syndrome, caused by inherited mutations of the BAP1 gene, was discovered by Carbone and his team at the UH Cancer Center in 2011. Since then, many affected families have been identified in the U.S., Europe, Australia, Japan and in the Middle East.

(Click Here to Continue Reading from source)

Exhaled breath analysis shows promise in detecting malignant pleural mesothelioma

by International Association for the Study of Lung Cancer

Medical Express


Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

Malignant pleural mesothelioma (MPM) is a challenging disease with limited treatment options and a poor prognosis. To improve treatment outcomes and tailor therapies for individual patients, researchers have been exploring predictive markers. Recently, volatile organic compounds (VOCs) in exhaled breath have emerged as potential non-invasive markers for disease.

Kevin Lamote, Ph.D., from the University of Antwerp, Belgium, and colleagues conducted a study aimed to investigate whether exhaled breath analysis could differentiate treatment responders from non-responders (discriminative setup) and, if successful, predict treatment outcomes earlier (predictive setup) using VOCs as predictive biomarkers.

(Click Here to Continue Reading from source)

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone

June 03, 2023

RAHWAY, N.J. & KINGSTON, Ontario–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy as first-line treatment for patients with unresectable advanced pleural mesothelioma. At the final analysis of the study, KEYTRUDA plus chemotherapy significantly improved overall survival (OS), reducing the risk of death by 21% (HR=0.79 [95% CI, 0.64-0.98]; two-sided p value=0.0324), with a median OS of 17.3 months (95% CI, 14.4-21.3) versus 16.1 months (95% CI, 13.1-18.2) for chemotherapy alone. These late-breaking data are being presented today during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #LBA8505) and are being discussed with regulatory authorities worldwide.

“Patients with pleural mesothelioma are usually diagnosed at an advanced stage, when the five year survival rate is only 12% and curative surgery is not an option,” said Dr. Lesley Seymour, Director of the Investigational New Drug program at CCTG, and Senior Investigator for IND.227. “The addition of pembrolizumab to platinum-pemetrexed in our study resulted in significantly improved overall survival, progression-free survival and objective response rates compared to platinum-pemetrexed alone, regardless of PD-L1 expression. This regimen represents a potential new treatment option for patients with advanced pleural mesothelioma.”

“These results support the potential of KEYTRUDA plus chemotherapy as a new first-line option for patients with advanced pleural mesothelioma, who currently have limited treatment options,” said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. “These data demonstrate our commitment to improving outcomes for patients with different types of thoracic cancer through our expansive clinical development program and research evaluating KEYTRUDA in new, difficult-to-treat tumors.”

(Click Here to Continue Reading from source)

‘Drug factory’ implants eliminate mesothelioma tumors in mice

RICE UNIVERSITY News and Media Relations Office of Public Affairs

Jade Boyd – Aug. 22, 2022

Rice, Baylor study highlights potential treatment for aggressive lung cancer

HOUSTON – (Aug. 22, 2022) – Rice University and Baylor College of Medicine researchers have shown they can eradicate advanced-stage mesothelioma tumors in mice in just a few days with a treatment combining Rice’s cytokine “drug factory” implants and a checkpoint inhibitor drug.

The researchers administered the drug-producing beads, which are no larger than the head of a pin, next to tumors where they could produce continuous, high doses of interleukin-2 (IL-2), a natural compound that activates white blood cells to fight cancer.

From left, Amanda Nash, Dr. Bryan Burt, Omid Veiseh and Samira Aghlara-Fotovat. (Photo by Jeff Fitlow/Rice University)

The study, published online today in Clinical Cancer Research, is the latest in a string of successes for the drug-factory technology invented in the lab of Rice bioengineer Omid Veiseh, including Food and Drug Administration (FDA) approval to begin clinical trials of the technology this fall in ovarian cancer patients.

“From the beginning, our objective was to develop a platform therapy that can be used for multiple different types of immune system disorders or different types of cancers,” said Rice graduate student Amanda Nash, who spent several years developing the implant technology with study co-lead author Samira Aghlara-Fotovat, a fellow student in Veiseh’s lab.

The cytokine factories consist of alginate beads loaded with tens of thousands of cells that are genetically engineered to produce natural IL-2, one of two cytokines the FDA has approved for treatment of cancer. The factories are just 1.5 millimeters wide and can be implanted with minimally invasive surgery to deliver high doses of IL-2 directly to tumors. In the mesothelioma study, the beads were placed beside tumors and inside the thin layer of tissue known as the pleura, which covers the lungs and lines the interior wall of the chest.

(Click Here to Continue Reading from source)

Tazemetostat for Pleural Mesothelioma Shows Encouraging Results

Monday, May 16, 2022

Medical oncologist Marjorie Zauderer says more than half of people with pleural mesothelioma have the mutation, BAP1, that is targeted by the drug.

Mesothelioma is a rare, aggressive cancer affecting the lining that surrounds organs. The most common form of the disease, pleural mesothelioma, develops in the tissue lining the lungs. The disease is very difficult to treat because it does not grow as a solid tumor and is usually not possible to remove with surgery. It can be controlled with drugs and radiation therapy but not cured. More than 50% of pleural mesotheliomas have a mutation called BAP1.

Now results of a clinical trial suggest that a drug called tazemetostat (Tazverik®) could be effective in a significant portion of people with pleural mesothelioma. The phase 2 trial, led by Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Marjorie Zauderer, showed that tazemetostat could control the disease in people whose pleural mesothelioma cells contain a BAP1 mutation.

“This is the first targeted therapy we’ve seen to have a real effect on slowing or stopping pleural mesothelioma,” Dr. Zauderer says. “Although targeted therapies have been successful with many other cancers, one problem with mesothelioma has been that there aren’t many alterations we can target. Now that is changing.”

The drug was given to 74 people whose cancer contained a BAP1 mutation and whose disease had progressed after they had received chemotherapy. The results were better than expected. Dr. Zauderer said that based on earlier trials of similar patients, doctors had expected tazemetostat to control the disease — keep it from getting worse — in 35% of people after 12 weeks. But in this new study, the drug controlled disease in 51% of patients.

(Click Here to Continue Reading from source)

Immunotherapy improves survival for people with aggressive, asbestos-linked lung cancer

by Cancer Research UK | News

Health & Medicine

30 January 2021

People with an aggressive form of lung cancer that’s come back after treatment, leaving them with limited options, could live longer when treated with an immunotherapy currently available for several types of cancer.

The trial, funded by Cancer Research UK’s Stand Up To Cancer campaign, found that the immunotherapy drug nivolumab increased survival and made the disease more stable for patients with relapsed mesothelioma when compared to those in the placebo group.

This is the first study to show that a treatment has been able to improve survival in patients with mesothelioma that’s come back after chemotherapy. The findings were presented at the World Conference on Lung Cancer today.

A ‘game-changer’

Mesothelioma develops in the lining of the lungs or abdomen, with most cases caused by exposure to the now outlawed industrial material, asbestos.

“Asbestos might seem like a threat of the past, but for many, it’s left quite literal scars that are only being seen now. Mesothelioma is a relatively rare disease, but it is a devastating one. We wanted to do anything we could to find better treatments for these patients, despite being in the midst of a global pandemic.” – Professor Dean Fennell, director of the Leicester Mesothelioma Research Programme, co-lead on the study

Cases of mesothelioma in the UK have increased by 61% since the early 1990s. Cases are particularly high in areas of the UK where shipping and mining industries formerly thrived. And in England, only 7% of people diagnosed with mesothelioma survive their disease for 5 years or more.

(Click Here to Continue Reading from source)

Life-saving new approaches for mesothelioma cancer recommended

UH News

May 3, 2022

Michele Carbone

The University of Hawaiʻi Cancer Center has published the latest research on preventive and therapeutic approaches for mesothelioma—a cancer of the membranes covering the chest and the abdomen—caused by inherited genetic mutations in the Journal of Thoracic Oncology.

Lead author Michele Carbone and his team found that patients with mesothelioma caused by BAP1 or other inherited genetic mutations, require a personalized, different preventive, early detection and therapeutic approach, compared to mesotheliomas not linked to genetic mutations. According to the researchers, these personalized approaches can significantly improve cancer prognosis for many years and save lives.

“The paper will help physicians in the U.S. and abroad to understand the unique aspects of mesothelioma in carriers of genetic BAP1 mutations. This will help them take better care of their patients and family members who may have inherited the defective BAP1 gene,” said Carbone.

Mutated genes can sometimes cause cancer. Germline mutations are those that people are born with. These mutations in the BAP1 gene can cause mesothelioma and other cancers. Researchers at the UH Cancer Center previously discovered that an estimated 10% of mesotheliomas are caused by inherited gene mutations such as BAP1. In this article, the authors report the clinical implications of this discovery.

The National Cancer Institute (NCI) recently opened two separate clinical trials in Bethesda, Maryland for mesothelioma patients and their family members with germline mutations of BAP1 and other genes. The NCI covers study costs for patients and family members enrolled in these clinical trials. The goal of these trials is to improve therapy, and identify the best strategies for early detection of cancers common among these patients.

(Click Here to Continue Reading from source)

CDC reports increase in mesothelioma deaths among women

Download PDF Copy

By Bhavana Kunkalikar May 17 2022Reviewed by Aimee Molineux

In a recent study published in the CDC’s Morbidity and Mortality Weekly Report, researchers analyzed the incidence of malignant mesothelioma mortality in females in the US.

Occupational exposure to asbestos is commonly reported by men working in industries including construction and manufacturing. Various studies have also reported the incidence of exposure to asbestos in women. However, there is limited data related to the occurrences of mortality caused by mesothelioma in women.

Study: Malignant Mesothelioma Mortality in Women — United States, 1999–2020. Image Credit: Robert Coolen / Shutterstock

About the study

In the present study, researchers characterized the deaths reported as related to mesothelioma and analyzed the temporal trends associated with mesothelioma mortality in women residing in the US.

The team identified deaths related to mesothelioma from 1999 to 2020 and also included any death certificates having the International Classification of Diseases, Tenth Revision (ICD-10) code for malignant mesothelioma. The analysis was restricted to the mortality reported in women aged 25 years and above due to the long latency observed in mesothelioma. The age-adjusted death rates were evaluated per each state to estimate the time trends in deaths across the country.

Furthermore, the team categorized various occupations as per the four-digit 2012 US Census Bureau coding system. As a result, the researchers found information related to industries and occupations for 92.3% of the total malignant mesothelioma deaths reported across 47 jurisdictions in the country.


The study results showed that the annual number of deaths related to mesothelioma among women increased substantially from 489 deaths in the year 1999 to 614 in 2020. However, the death rate per one million women was 4.83 in 1999 which reduced significantly to 4.15 in 2020. Moreover, the highest number of deaths due to mesothelioma was observed in the health care and social assistance industry and the homemaker occupation.

(Click Here to Continue Reading from source)

Number of mesothelioma deaths up among women from 1999 to 2020


MAY 13, 2022

From 1999 to 2020, there was an increase in the annual number of mesothelioma deaths among women, although the age-adjusted death rate decreased, according to research published in the May 13 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Noting that inhalation of asbestos fibers can cause malignant mesothelioma, Jacek M. Mazurek, M.D., from the CDC in Atlanta, and colleagues analyzed annual Multiple Cause of Death records from the National Vital Statistics System for 1999 to 2020 to characterize deaths associated with mesothelioma and temporal trends in mesothelioma mortality among women.

The researchers observed a significant increase in the annual number of mesothelioma deaths among women, from 489 in 1999 to 614 in 2020; however, there was a significant decrease in the age-adjusted death rate per 1 million women, from 4.83 to 4.15 in 1999 and 2020, respectively. The largest number of deaths was associated with the health care and social assistance industry and the homemaker occupation (15.7 and 22.8 percent, respectively).

(Click Here to Continue Reading from source)

EWG-Commissioned Tests Finds Cancer-Causing Asbestos in Talc-based Cosmetics

Nov 25, 2020

Earlier this year, EWG reported results of tests that found the notorious carcinogen asbestos in samples of talc-based cosmetics. EWG-commissioned tests by Scientific Analytical Institute found asbestos in three of 21 cosmetics products, including two eye shadow palettes and one toy makeup kit marketed to children.

After we alerted parents and consumers about these hazardous products, Amazon and Ebay removed them from their websites. Now our short report on the findings has been published in Environmental Health Insights, a peer-reviewed scientific journal.

EWG’s research is the latest in a growing body of scientific evidence drawing attention to the prevalence of asbestos contamination in personal care products and the lack of regulation to protect consumers from the health risks associated with this mineral. Last year, the Food and Drug Administration found asbestos in nine of the 52 talc-based products tested, numbers akin to our findings.

The Occupational Safety and Health Administration, or OSHA, warns there is no “safe” level of exposure to asbestos. It is linked to several types of cancers, including mesothelioma and the scarring lung disease asbestosis. Talc-based cosmetics, particularly products in powdered form, can be inhaled when applied to the face, but users are often unaware of this risk.

Talc is a mineral ingredient mined from rock that can also commonly contain asbestos minerals. It is used in numerous makeup and personal care products, such as eye shadow, face powder, body powder and blush. A survey of EWG’s Skin Deep® database found more than 2,000 products contain talc, almost 60 percent of which are powders. Skin Deep is a searchable, online resource that rates more than 80,000 personal care products based on the hazards associated with their ingredients.

(Click Here to Continue Reading from source)

Missouri Court Cuts Talc-Powder Verdict Against J&J to $2.1 Billion

Appeals court upholds jury’s verdict in Johnson’s Baby Powder case, while reducing the damages J&J must pay by more than half

J&J said in May it will stop selling talc-containing baby powder in the U.S. and Canada.


By Peter Loftus June 23, 2020 3:15 pm ET

A Missouri appeals court on Tuesday upheld a jury verdict that Johnson & Johnson’s talcum powder caused ovarian cancer in 22 women, though the court reduced by more than half the $4.69 billion in damages J&J was ordered to pay.

The Missouri Court of Appeals reduced total damages to about $2.1 billion. J&J earlier Tuesday said the new amount was about $2.2 billion but subsequently said it was $2.1 billion.

The 2018 verdict, following a six-week trial in state court in St. Louis, was the biggest award of damages in a series of trials arising from lawsuits over the safety of Johnson’s Baby Powder, as well another talc-containing powder, Shower to Shower, that J&J used to sell.

J&J said the 2018 trial in St. Louis “was a fundamentally flawed trial, grounded in a faulty presentation of the facts.” The company said it will pursue further review of the case by the Supreme Court of Missouri.

Read More…

A New Study Suggests Tainted Talcum Powder Can Cause a Rare Cancer. Here’s How That Could Play Out in the Courtroom



Anew 33-patient case study published in the Journal of Occupational and Environmental Medicine provides some of the strongest proof yet that exposure to asbestos-tainted talcum powder may cause malignant mesothelioma, a rare and deadly cancer that affects tissues lining internal organs.

This isn’t only an important scientific discovery—it could also give new ammunition to plaintiffs in the thousands of cases brought against brands selling talcum-powder-based products alleged to cause cancer, like Johnson & Johnson’s Baby Powder.

“It’s very, very hard, in general, to prove exactly what caused your specific case of disease,” says Steve Gold, a professor at Rutgers Law School who specializes in toxic and hazardous substances. “If a credible physician and researcher is willing to testify and has published that these individual cancers appear to be caused by asbestos exposure from talcum powder, that’s evidence that is usually not available to plaintiffs. That’s very powerful.”

Asbestos is a group of naturally occurring fibrous minerals that’s considered a human carcinogen by the World Health Organization and other public health groups. It is linked to mesothelioma, ovarian cancer and lung cancer. Among other places, it’s found in building supplies, insulation, some car parts—and the talc from which talcum powder is made. (Talc also turns up in cosmetics like blush and facial makeup.) Since the 1970s, manufacturers have pledged to use talc that is free from detectable levels of asbestos, but there is still little regulation over the cosmetic industry, and concerns about asbestos contamination persist. A bombshell 2018 Reuters report also found that J&J knew for decades that some of its Baby Powder was tainted by asbestos, but did not report that information publicly or to federal regulators.

Read More…

FDA Approves Drug Combination for Treating Mesothelioma

October 02, 2020

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.

“Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “In 2004, FDA approved pemetrexed in combination with cisplatin for this indication, and now patients now have an important, additional treatment option after more than a decade with only one FDA-approved drug regimen.”

Malignant pleural mesothelioma (MPM) is a life-threatening cancer of the lungs’ lining caused by inhaling asbestos fibers that about 20,000 Americans are diagnosed with each year. MPM accounts for most mesothelioma diagnoses, and most patients have an unresectable (unable to be removed with surgery) tumor at time of diagnosis. With currently available therapy, overall survival is generally poor. Opdivo and Yervoy are both monoclonal antibodies that, when combined, decrease tumor growth by enhancing T-cell function.

Read More…

UHRF1 May Be an Actionable Target in Malignant Pleural Mesothelioma

October 8, 2020 Susan Moench, PhD, PA-C

UHRF1 is overexpressed in several human malignancies, and may drive tumorigenesis by silencing tumor promoter genes through hypermethylation.

Regulation of expression of the protein called ubiquitin-like with plant homeodomain and ring finger domains 1 (UHRF1) may impact survival in patients with malignant pleural mesothelioma, according to findings published in the Journal of Thoracic Oncology.

UHRF1 is a protein encoded by the UHRF1 gene. It is a component of multiprotein complex that is involved in recruiting DNMT1, a DNA methyltransferase, that catalyzes the transfer of methyl groups to specific CpG structures in DNA. UHRF1 is overexpressed in several human malignancies, and may drive tumorigenesis by silencing tumor promoter genes through hypermethylation, as well as activating endogenous retroviral sequences through hypomethylation.

The aim of this study was to investigate the potential role of UHRF1 as an epigenetic driver in malignant pleural mesothelioma.

Read More…

Doctor showcases new FDA-approved treatment for Mesothelioma

By Stella Porter

Published: Sep. 8, 2020 at 2:57 PM PDT

(WZAW) – Each year, an estimated 3,000 Americans are diagnosed with mesothelioma, a rare type of cancer that forms in the lining of major organs in the chest or stomach. Over 70% of people diagnosed with mesothelioma have been exposed to asbestos, making it the leading cause of the disease.

The most common form is malignant pleural mesothelioma, but less than 30% of patients were candidates for surgery to remove the tumor, according to a SEER-Medicare data set analysis in elderly MPM patients, opening the door for new and innovative treatments. In 2019, the FDA approved a new treatment for MPM called Optune Lua, which is the first treatment approved by the FDA for the disease in more than 15 years. Optune Lua is a wearable and portable cancer treatment that delivers Tumor Treating Fields to the region of the tumor. TTFields are low-intensity alternating electric fields tuned to specific frequencies that continuously disrupt cancer cell division.

Read More…

Chemotherapy/immunotherapy combo shows promise for first-line treatment of mesothelioma

Date: June 11, 2020

Source: Science News Johns Hopkins Medicine


Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. At the annual meeting of the American Society of Clinical Oncology (ASCO), held virtually from May 29-31, 2020, a researcher from the Johns Hopkins Kimmel Cancer Center presented findings from a multicenter study that evaluated the efficacy of an immunotherapy-plus-chemotherapy combination for the disease.

According to Patrick Forde, M.B.B.Ch., associate professor of oncology at the Johns Hopkins University School of Medicine, director of the Kimmel Center’s thoracic cancer clinical research program and a Bloomberg~Kimmel Institute for Cancer Immunotherapy investigator, the study looked at 55 patients from 15 U.S. cancer centers who received the immunotherapy drug durvalumab in combination with two anticancer chemotherapies — cisplatin and pemetrexed — to create a novel first-line treatment.

Read More…

Breaking Research News from Annual Meeting of American Society of Clinical Oncology

10-Jun-2020 1:15 PM EDT, by Johns Hopkins Medicine

Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for cancer patients. Two of this year’s presenters include winners of ASCO Young Investigator and Merit Awards. The meeting was held virtually May 29–31.

Presentations included:

— Chemotherapy/Immunotherapy Combo for First-Line Treatment of Mesothelioma
A clinical study, called PrE0505, evaluated the efficacy of an immunotherapy-plus-chemotherapy combination for inoperable malignant pleural mesothelioma, a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. The study, presented by Patrick Forde, M.B.B.Ch., associate professor of oncology, director of the Kimmel Cancer Center’s thoracic cancer clinical research program and a Bloomberg~Kimmel Institute for Cancer Immunotherapy investigator, included 55 patients from 15 U.S. cancer centers who received the anti-PD-L1 immunotherapy drug durvalumab in combination with the anticancer chemotherapies cisplatin and pemetrexed as a first treatment.

Patients received six treatments of the combination therapy every three weeks followed by treatment with the immunotherapy durvalumab for up to one year in total. The chemo-immunotherapy combination improved overall survival from historical expected survival of 12 months with chemotherapy alone to 20.4 months with the chemo-immunotherapy combination. This is the first study to show survival exceeding 20 months for patients with inoperable mesothelioma. Treatment was well-tolerated overall with no unexpected side effects reported.

Read More…

Radiotherapy doubles survival for patients with mesothelioma

Date: April 29, 2019

Source: Science News

European Society for Radiotherapy and Oncology (ESTRO)


Mesothelioma patients are twice as likely to survive for two years or longer, if they are treated with a high dose of radiation to the affected side of the trunk.

Mesothelioma patients are twice as likely to survive for two years or longer, if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented at the ESTRO 38 conference.

Mesothelioma is a rare but aggressive form of cancer that grows in the layers of tissues surrounding the lungs. It is usually caused by exposure to asbestos. Patients typically only live for a year or two following diagnosis and treatment options are very limited.

The study looked at patients whose cancers could not be completely removed with surgery and the researchers say their findings have the potential to change treatment and outcomes for this group of patients.

The study was led by Dr Marco Trovo MD, chief of the Radiation Oncology Department at University Hospital of Udine, Italy. He said: “There is an urgent need for more effective treatments for mesothelioma. Surgery can be given to these patients, but it is often impossible to remove all of the tumour.

“Patients with mesothelioma are sometimes given radiotherapy to help control their symptoms. However, radiotherapy has evolved dramatically in the last few years so we wanted to see if it could now be used to prevent the cancer from spreading to nearby tissue, hopefully bringing improvements in survival.”

The study involved 108 patients with malignant pleural mesothelioma who were treated at the National Cancer Institute of Aviano, Italy, between 2014 and 2018. All were given surgery to remove some tumour tissue, followed by chemotherapy.

Read More…

Disease-Related Characteristics and Asbestos Exposure in Women With Mesothelioma

Susan Moench, PhD, PA-C March 6, 2020

Although some studies have addressed rates of mesothelioma in women, few have provided correlation with physical evidence of asbestos exposure.

Results of a retrospective study of a series of patients with malignant diffuse mesothelioma from a single institution showed that most women with the disease had a history of household exposure to a worker in industries that used asbestos. These findings were reported in the American Journal of Surgical Pathology.

Although the association between asbestos exposure and mesothelioma, occurring in either the pleura or peritoneum, has been well established, the focus of many of the studies of patients with mesothelioma has been on men exposed to asbestos through their occupation. Although some studies have addressed rates of mesothelioma in women, few have provided correlation with physical evidence of asbestos exposure, and data related to the location and histopathology of the disease in women, their history of asbestos exposure, as well as their survival are scarce.

In this study, cases of mesothelioma histologically confirmed between 1983 and 2010 were identified through a review of a medical records database from a single institution. Of the 2858 cases identified, 354 (12.4%) occurred in women, with 78% and 22% of these cases diagnosed as pleural mesothelioma and peritoneal mesothelioma, respectively.

Read More…

J&J Ordered by Jury to Pay $9 Million in Talc-Cancer Case

By Jef Feeley | February 28, 2020

Johnson & Johnson was ordered by a Florida jury to pay $9 million to an 82-year-old woman who blamed asbestos-tainted talc for her cancer, the latest court loss for the company in U.S. litigation over its iconic baby powder.

Jurors in Miami concluded on Thursday that asbestos in baby powder used by Blanca Mure-Cabrera over her lifetime contributed to the development of her mesothelioma, said David Jagolinzer, one of her lawyers. That type of cancer has been specifically linked to asbestos exposure.

The trial loss is the second for J&J this year over claims the company knew some of its talc-based products were laced with asbestos and hid it from consumers. Earlier this month, a jury in J&J’s hometown of New Brunswick, New Jersey, ordered the company to pay $750 million in punitive damages to four people. A judge later reduced that award to $186.5 million.

J&J — the world’s largest maker of healthcare products — said it will appeal the jury’s liability finding and damage award.

“Today’s verdict is at odds with the decades of evidence showing the company acted responsibly and was guided by sound science,” Kim Montagnino, a company spokeswoman, said in an emailed statement.

J&J still faces almost 18,000 lawsuits over the 135-year-old baby powder. A majority of the cases allege women who used the product got ovarian cancer, while a smaller number claim links to mesothelioma.

The talc litigation may eventually cost the company as much as $10 billion, according to Bloomberg Intelligence. Though baby powder accounts for only a small fraction of J&J’s annual revenue, it’s been a core brand for the company for more than a century.

Read More…

How Technology Is Transforming Healthcare for Mesothelioma Patients

ARTICLE  Feb 25, 2020 | By Colin Ruggiero

Micrograph of mesothelioma with ferruginous bodies.

Technology and cancer

Oncology, like other areas of healthcare, relies on technology. Three dimensional (3D) bioprinting and artificial intelligence (AI) have been fundamental technologies for understanding disease and contributing to groundbreaking research. Within the past year, technological developments have provided opportunities for early diagnosis and targeted treatment for mesothelioma patients.

Why mesothelioma?

Mesothelioma patients are typically diagnosed in the late cancer stages, leaving them with inadequate treatment options. As with any disease, early diagnosis is paramount. However, since mesothelioma has a prolonged latency period, it may not be discovered for over 45 years after initial exposure.

Although researchers are looking into other potential causes, asbestos exposure is the most apparent and thought to be the most common cause of mesothelioma. Asbestos was a mineral previously used in a variety of products, as well as being a common additive in homes and buildings from the 1930s to 1980s, due to its low price, flame-resistant properties, and suitability for industrial projects. It continues to threaten society through second and third-wave exposure due to deterioration and construction. The United States Environmental Protection Agency (EPA) aims to protect the public from exposure to asbestos; today the USA tolerates just 1% of asbestos in commercial goods.

Although there are only 3,000 new mesothelioma cases each year, veterans make up 30% of this population. Additionally, every year 1.3 million construction workers come into contact with asbestos. Other at-risk occupations include civil engineers, making up 3.9% of mesothelioma deaths in 1999, and research indicates that any worker exposed to asbestos has a 10% chance of developing mesothelioma.

For those who encountered this carcinogenic fiber, their prognosis is then cut by both age and the tumor’s growth to inoperable and inaccessible organs. However, developments in AI and 3D bioprinting have led to the possibility of a revised treatment plan, with which mesothelioma patients could have an improved chance at survival.

Read More…

Cost of Cancer Care Reaches Nearly $150B Nationally

January 15, 2020 – Price tags of life-saving treatments are continuing to increase, with nearly $150 billion being spent nationally per year for cancer care, four times more than treatment for other common health conditions, according to a report from The Mesothelioma Center. 

Sixty-three percent of cancer patients faced financial struggles following a cancer diagnosis.

Cancer treatment costs were reported highest among preventable cancers such as lung cancer, colorectal cancer, breast cancer, and mesothelioma. Specifically, the lifetime cost of lung cancer was an estimated $282,000 while mesothelioma was a reported $150,000.

Read More…

50 patients with malignant mesothelioma of both the pleura and peritoneum: A single-institution experience

Annals of Surgical Oncology — Letica-Kriegel AS, Leinwand JC, Sonett JR, et al. | December 24, 2019

Researchers sought to determine the overall survival from the initial operative intervention in 50 patients with both pleural and peritoneal mesothelioma treated with the intent to prolong survival. The patients had the median overall survival of 33.9 months from the initial intervention. Independent predictors of overall survival were female gender and intraperitoneal dwell chemotherapy. As per findings, a survival benefit could be achieved in well-selected patients with both pleural and peritoneal mesothelioma over palliative treatment that is similar to that observed in the single-cavity disease. Multimodality treatment aimed at prolonging survival should not be contraindicated in the presence of disease in both cavities, whether the disease is diagnosed synchronously or metachronously. Among patients with an initial diagnosis of single cavity disease, the second-cavity disease occurred most frequently within the first year after diagnosis.

Read More…

Mutations in DNA Repair Pathway Genes Found to Be Prevalent in Mesothelioma

January 15, 2020 – Leah Lawrence – Cancer Therapy Advisor

Variants in DNA damage repair genes may play a role in the pathogenesis of malignant pleural mesotheliomas, according to a recent study by researchers from Memorial Sloan Kettering Cancer Center.

The investigators used the MSK-IMPACT next-generation sequencing platform to screen 84 patients with mesothelioma for cancer-predisposing genes.

Using blood samples, they found that 12% of the patients had a pathogenic variant. The majority of mutations found were associated with DNA damage repair.

Although clinical characteristics were similar between patients with and without variants, those with variants were more than twice as likely to have 2 first-degree family members with cancer than those without (40% vs 12%; <.05).

Among the novel variants identified with the testing were MSH3, BARD1, and RECQL4. Also confirmed were several variants that had been identified in previous studies including BAP1 (4%), BRCA2 (1%), and MRE11A (1%).

Read More…

Two-drug combination could be effective against malignant mesothelioma

Reviewed by Kate Anderton, B.Sc. (Editor) Jan 8 2020

Exposure to asbestos is the major risk factor for malignant mesothelioma, a type of aggressive cancer that mostly affects the pleura – the tissue that lines the lungs – and the peritoneum – the tissue that lines the abdomen. This has been known for decades, yet the molecular characterisation of mesothelioma is barely known and treatment options are scarce. A study carried out by researchers at the Spanish National Cancer Research Centre (CNIO) on key molecular processes in this type of cancer identified two drugs that, used in combination, could be effective against the most aggressive type of mesothelioma. The compounds are already being used in clinical trials for other tumours, a fact that might help speed up studies on mesothelioma patients.

Read More…

Targovax Announces Encouraging Data in Mesothelioma Study

PR Newswire –  January 21, 2020

OSLO, Norway, Jan. 21, 2020 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the first set of clinical results from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM).

The trial is an open label, exploratory phase I/II adding ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first and second (or later) line MPM to assess safety, immune activation and clinical efficacy of the combination treatment. In total, 31 patients have been enrolled in the randomized trial design, with 20 patients in the experimental group receiving the ONCOS-102 and SoC combination, and 11 patients in a control group receiving SoC only. All patients have completed the treatment phase (4 months for the control group and 5 months for the experimental group) and the first data have been analyzed. The combination treatment with ONCOS-102 and SoC was well tolerated, with no safety signals beyond what is expected from SoC alone.

Read More…

Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases: New Statistics Released

Am J Surg Pathol. 2019 Dec 23

We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% pleural MM and 22% peritoneal MM. The pleural tumors consisted of 72% epithelioid, 19% biphasic, and 9% sarcomatoid variant. The peritoneal tumors consisted of 82% epithelioid, 13% biphasic, and 5% sarcomatoid. The immunohistochemical profile was typical of what is well-accepted and previously described for MM. When examining tumor subtype and location, there was a trend toward epithelioid subtype and peritoneal location; however, this did not reach statistical significance. Age at the time of diagnosis ranged from 19 to 93 years with a mean of 60 years. The median age at time of diagnosis for pleural MM was 65 years and for peritoneal MM was 52 years. A further look at age and histologic subtype showed no statistically significant difference in age between MM subtypes. Survival was greatest for epithelioid variant, and this was magnified in the peritoneum. A majority of our cases were exposed to asbestos through a household contact. Asbestosis and parietal pleural plaque were present in 5% and 50% of cases with data, respectively. Fiber analysis data was available in 67 cases; 38 cases had elevated asbestos fiber burden, and tremolite was the most common asbestos fiber type detected. Commercial and noncommercial amphibole asbestos fibers were elevated in nearly equal numbers of cases.

Read More…

US steps up scrutiny of funds for asbestos exposure victims

By ERIC TUCKER October 31, 2018 AP News

FILE – In this May 14, 2013, file photo, the Department of Justice headquarters building in Washington is photographed early in the morning. The Trump administration has stepped up scrutiny of asbestos trust funds out of concern of fraud and abuse. The Justice Department worries the pots of money intended to help pople exposed to the hazardous substance are being depleted by fraudulent claims _ harming victims, businesses and the government. (AP Photo/J. David Ake, File)

WASHINGTON (AP) — The Trump administration has stepped up scrutiny of asbestos trust funds, concerned that the pots of money intended to help people exposed to the hazardous substance are being depleted by fraudulent claims, harming victims, businesses and the government.

The Justice Department in the last two months has demanded trust documents as part of a civil investigation, opposed the creation of another trust it said lacked sufficient safeguards, and argued against the appointment of a lawyer it said was too conflicted to represent victims.

The actions take aim at a system that over decades has paid out billions of dollars to the sick and cancer-stricken, but that critics say is opaque and prone to fraud and manipulation by well-connected lawyers. The government’s intervention aligns it with business groups who have long complained about the process.

“We have an interest in fraud and consumer protection, so if there is fraud happening out there that is cognizable under federal law, that’s the type of thing the Justice Department tends to get interested in,” acting Associate Attorney General Jesse Panuccio said in an interview.

Read More…

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray BSc, MSc, PhD Jacques Ferlay ME Isabelle Soerjomataram MD, MSc, PhD

First published: 12 September 2018

This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high‐quality cancer registry data, the basis for planning and implementing evidence‐based cancer control programs, are not available in most low‐ and middle‐income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1‐31. © 2018 American Cancer Society

Read More…

Early Screening Key to Reducing Lung Cancer Deaths


PUBLISHED: November 24, 2018 at 12:00 am | UPDATED: July 11, 2019 at 12:00 am

By Dr. Andrea McKee

Lung cancer is the leading cancer killer in the U.S. even though it is highly curable if detected at an early stage.

Yet less than 2 percent of the at least 9 million Americans who are eligible for lung-cancer screening are getting tested for the disease. And according to a study reported last month, the benefits of lung-cancer screening are even greater than the medical community realized, reducing mortality by 26 percent for high-risk men and up to 61 percent for high-risk women.

The low lung-cancer screening rates are in stark contrast to the over 70 percent of women eligible for breast-cancer screening who have undergone a mammogram within the past two years. The medical community agrees early detection through screening has contributed to the significant decline in breast cancer death rates since the late 1980s. While the overall death rate from cancer in the U.S. has declined over the last two decades thanks to advances in primary prevention, early detection, and treatment, work must now be done by medical centers across the country to raise the low screening rates for those at high risk of developing lung cancer.

The American Lung Association recommends high-risk individuals get screened annually. Those considered at “high risk” for developing lung cancer are 55-80 years of age, have smoked one pack of cigarettes a day for 30 years or two packs a day for 15 years and are a current smoker or have quit within the last 15 years. Screening is done with a low-dose CT scan, which uses approximately ten times less radiation than traditional tests, to scan the body and create detailed pictures of the lungs. Clinicians then review the images to look for signs of lung cancer.

Read More…

Opioid switching and variability in response in pain cancer patients

June 2019, Volume 27, Issue 6, pp 2321–2327

  1. Corli – A. Roberto – N. Corsi – F. Galli -M. Pizzuto

Opioid switching is a possible strategy for inadequate analgesia or unmanageable side effects. Its effectiveness ranges from 50 to 90% and is still debated.


We analyzed the impact of opioid switching in a cancer pain population treated with strong opioids for pain.


This is a post hoc analysis from a multicenter, randomized, four-arm, controlled, phase IV clinical trial. Outcome variables included the percentages of switches, the reasons for the switch, the dose changes before and after the switch, depending on the starting opioid, the response in case of inadequate analgesia, and unmanageable toxicity, and the variability of response among and within patients.


We analyzed 498 patients. The opioid was switched in 79 patients (15.9%) 87 times, mainly for uncontrolled pain (52.3%), adverse opioid reactions (22.1%), both of these (4.8%), and dysphagia (20.8%). The reasons for switching varied depending on the starting opioid. Pain reduction was good after 51.45% of switches and control of opioid side effects was good after 43.5%. The relief of opioid-induced toxicity varied among adverse events and within each patient. The daily doses were higher after switching oral opioids and lower after transdermal drugs.

Read More…

The Justice Department will continue to look for opportunities to increase the transparency of asbestos trusts and protect the interests of legitimate claimants and the United States. 

Thursday, September 13, 2018

The Department of Justice today filed a Statement of Interest in In re Kaiser Gypsum Co. in the United States Bankruptcy Court for the Western District of North Carolina.  In the case, Kaiser Gypsum Company and Hanson Permanente Cement Inc. propose the establishment of a new asbestos trust under 11 U.S.C. § 524(g), a section of the Bankruptcy Code that provides the framework for responding to the unique issues associated with asbestos liability.

“In recent years, alarming evidence has emerged of fraud and mismanagement inside asbestos trusts,” said Principal Deputy Associate Attorney General Jesse Panuccio.  “Asbestos victims should feel certain that they will receive compensation when they are promised it, but fraudulent claims and mismanagement call that promise into question. In addition, the United States and all who depend on Medicare are harmed when Medicare is not reimbursed for treatment costs that have been paid by trust funds. With today’s Statement of Interest, the Department sends a clear message that we will not tolerate fraudulent conduct that cheats asbestos victims and the United States.  This is just one action the Department will take to increase the transparency and accountability of asbestos trusts, and we are grateful for the many partners we have in that mission, including the many state attorneys general who have brought attention to this issue.  We encourage anyone with information about fraud or mismanagement of asbestos trusts to report it to the Department of Justice.”

Congress enacted 11 U.S.C. § 524(g) to create a comprehensive mechanism for addressing injuries caused by asbestos.  Under section 524(g) plans, asbestos-related claims may be channeled to a special trust created under the bankruptcy plan of reorganization, which then assumes responsibility for both the defense and payment of those claims.  The trusts are managed by trustees, who often must secure support for major decisions from a “trust advisory committee” (TAC), whose members are often the same attorneys who represented asbestos claimants during the bankruptcy.  Since 1994, more than 60 such trusts have been established by chapter 11 debtors with asbestos-related liabilities.  According to the Government Accountability Office, asbestos bankruptcy trusts paid $17.5 billion from 1988 through 2011, and more recent studies estimate higher amounts.

Read More…

Radiation Could Make Mesothelioma Immunotherapy More Effective

Non-ablative hypofractionated hemithoracic radiation—a new standard of care in mesothelioma? 

Marc de Perrot1 , John Cho2 1 Division of Thoracic Surgery, 2 Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada Correspondence to: Marc de Perrot, MD, MSc, FRCSC. Division of Thoracic Surgery, Toronto General Hospital, 9N-961, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada. Email: Provenance: This is an invited Editorial commissioned by the Section Editor Laura Chiara Guglielmetti (Cantonal Hospital Winterthur, Kantonsspital Winterthur, Winterthur, Switzerland). Comment on: Parisi E, Romeo A, Sarnelli A, et al. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment. Cancer Radiother 2017;21:766-73. Submitted Sep 16, 2018. Accepted for publication Sep 25, 2018. doi: 10.21037/jtd.2018.09.131 V

The role of radiation therapy in malignant pleural mesothelioma (MPM) has been explored for the past 50 years. Originally, MPMs were thought radioresistant tumors. However, experimental evidence suggested otherwise (1). For instance, in vitro studies have shown that mesothelioma cell lines were more sensitive to radiation than non-small cell lung cancer cell lines, experiments in mice models of mesothelioma have shown response to radiation therapy, clinical studies have demonstrated benefit of radiation in the palliative setting when specific areas of the chest were targeted, and hemithoracic radiation have shown good local control when combined with radical surgery [see review in (1) for specific references]. While palliative radiation has been delivered with hypofractionated regimen of at least 3 Gy per daily fraction, normofractionated doses (2 Gy per daily fraction) has typically been used in the setting of conventional hemithoracic radiation. The publication from Parisi and colleagues with accelerated hypofractionated hemithoracic radiation in the adjuvant setting after pleurectomydecortication (PD) or tumor biopsy as well as our experience with accelerated hypofractionated hemithoracic radiation in the induction setting raise the question as to whether hypofractionated rather than normofractionated radiation should be used for hemithoracic radiation (2,3). Hypofractionated radiation has several advantages.

Read More…

Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis

Published: 11 October 2018 – Molecular Cancer volume 17, Article number: 148 (2018)

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery of soluble biomarkers with diagnostic/prognostic and/or therapeutic properties would improve therapeutic care of MPM patients. Currently, soluble biomarkers described present weaknesses preventing their use in clinic. This study aimed at evaluating brain-derived neurotrophic factor (BDNF), we previously identified using transcriptomic approach, in MPM. We observed that high BDNF expression, at the mRNA level in tumors or at the protein level in pleural effusions (PE), was a specific hallmark of MPM samples. This protein presented significant but limited diagnostic properties (area under the curve (AUC) = 0.6972, p < 0.0001). Interestingly, high BDNF gene expression and PE concentration were predictive of shorter MPM patient survival (13.0 vs 8.3 months, p < 0.0001, in PE). Finally, BDNF did not affect MPM cell oncogenic properties but was implicated in PE-induced angiogenesis. In conclusion, BDNF appears to be a new interesting biomarker for MPM and could also be a new therapeutic target regarding its implication in angiogenesis.

Read More…

Malignant Mesothelioma Cancer Early Detection Getting Closer with Blood Test

Scientific Reports volume 8, Article number: 14321 (2018)  Published: 25 September 2018

Malignant mesothelioma (MM) is strongly associated with a previous asbestos exposure. To improve timely detection of MM in asbestos workers, better screening tools – like minimally-invasive biomarkers – are desirable. Between 2008 and 2018 2,769 patients with benign asbestos-related diseases were recruited to participate in annual screens. Using a nested case-control design the protein markers calretinin and mesothelin were determined by enzyme-linked immunosorbent assays in prediagnostic plasma samples of 34 MM cases as well as 136 matched controls from the cohort. Conditional on a pre-defined specificity of 98% for calretinin and 99% for mesothelin the markers reached individual sensitivities of 31% and 23%, respectively, when including the incident cases with samples taken between one and 15 months before diagnosis. The combination of both markers increased the sensitivity to 46% at 98% specificity. Marker complementation increased with earlier sampling. The marker combination improves the sensitivity of the individual markers, indicating a useful complementation and suggesting that additional markers may further improve the performance. This is the first prospective cohort study to evaluate a detection of MM by calretinin and its combination with mesothelin up to about a year before clinical diagnosis. Whether an earlier diagnosis will result in reduced mortality has yet to be demonstrated.

Read More…

Short‐term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma

Wiley Online Library – First published: 07 October 2018


We evaluated postoperative mortality and complications after extrapleural pneumonectomy (EPP) and pleurectomy decortication (P/D) to better understand their effectiveness in malignant pleural mesothelioma (MPM).


A meta‐analysis was done to evaluate 30‐day mortality and postoperative complications. In addition, in‐patients data of 500 eligible patients with MPM who underwent EPP or P/D was extracted from the New York Statewide Planning and Research Cooperative System (SPARCS). Multivariate analyses and propensity matching were used to compare in‐hospital mortality and postoperative complications in EPP vs P/D.


The meta‐analysis showed a statistically significant difference in 30‐day mortality (5% [95% CI: 4‐6] vs P/D 2% [95% CI: 1‐3]), proportion of complications (46% [95% CI: 36‐56] vs 24% [95% CI: 15‐34]) and postoperative arrhythmias (20% [95% CI: 12‐31] vs 5% [95% CI: 2‐8]) for EPP vs P/D. In‐hospital mortality (OR adj: 2.6; 95% CI: 0.86‐7.75) and postoperative complications (OR adj: 1.1; 95% CI: 0.68‐1.86) were not different in EPP compared with P/D while supraventricular arrhythmia was significantly more frequent after EPP vs P/D (OR adj: 5.2; 95% CI: 2.34‐11.33).

Read More…

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST)

Study Description Brief Summary: January 28, 2019

MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.

The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving survival outcomes for patients with mesothelioma.

Stage 1 – molecular pre-screening:

The MiST Master protocol describes the identification of patients, biomarker testing and analysis. Patients with relapsed mesothelioma will be offered to consent for molecular panel testing of their diagnostic tumour block for predictive biomarkers. The results of this assessment will be used to classify patients into one of several possible molecularly defined treatment arms. Patients will therefore be offered a specific study treatment determined by their molecular profile. Patients, who exhibit positive testing in more than one biomarker, will potentially be eligible to subsequently be treated on a different treatment protocol upon disease progression or treatment failure.

Stage 2 – Treatment:

The MiST treatment protocol will be specific to the treatment allocated to the patient – based on the results of their biomarker testing in stage 1.

Specific agent(s) will be detailed separately in each of the separate treatment protocols.

Stage 3 – Molecular Profiling :

In order to understand the genomic basis of drug response in the MiST trial, archival tumour tissue from all patients enrolled will be interrogated using molecular inversion probe- based microarray analysis of the somatic copy number aberrations. Optional re-biopsy of patients who progress on treatment, followed confirmed radiological response, will be offered, to investigate genomic interrogation of tumours at the time of acquired resistance. For arms 3 and 4, immune checkpoint, transcriptomic and gut microbiome correlative studies are planned.

Read More…

Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival

Science Direct – November 2018, Pages e901-e912


For the 3 histologic subtypes of malignant pleural mesothelioma (MPM)—epithelioid, sarcomatoid, and biphasic—the magnitude of benefit with surgical management remains underdefined.

Materials and Methods

The National Cancer Data Base was queried for newly diagnosed nonmetastatic MPM with known histology. Patients in each histologic group were dichotomized into those receiving gross macroscopic resection versus lack thereof/no surgery. Kaplan-Meier analysis evaluated overall survival (OS) between cohorts; multivariable Cox proportional hazards modeling assessed factors associated with OS. After propensity matching, survival was evaluated for each histologic subtype with and without surgery.


Overall, 4207 patients (68% epithelioid, 18% sarcomatoid, 13% biphasic) met the study criteria. Before propensity matching, patients with epithelioid disease experienced the highest median OS (14.4 months), followed by biphasic (9.5 months) and sarcomatoid (5.3 months) disease; this also persisted after propensity matching (P < .001). After propensity matching, surgery was associated with significantly improved OS for epithelioid (20.9 vs. 14.7 months, P < .001) and biphasic (14.5 vs. 8.8 months, P = .013) but not sarcomatoid (11.2 vs. 6.5 months, P = .140) disease. On multivariable analysis, factors predictive of poorer OS included advanced age, male gender, uninsured status, urban residence, treatment at community centers, and T4/N2 disease (all P < .05). Chemotherapy and surgery were independently associated with improved OS, as was histology (all P < .001).

Read More…

Current treatments and trials in malignant pleural mesothelioma

Anna C. Bibby Nick A. Maskell – First published: 01 August 2018 – SERIES ON PLEURAL DISEASES


This article aims to review the evidence from recent clinical trials in mesothelioma, and to provide an overview of relevant clinical trials that are currently in progress.

Data source

Ovid MEDLINE, 1946 to present.

Study Selection

Clinical trials of therapeutic interventions were considered for inclusion, regardless of phase. Of 258 papers identified in the literature search, 88 were potentially eligible based on abstract screening. Following evaluation of full‐text articles, 35 were selected for inclusion in the review.


Since the original trial that demonstrated the efficacy of pemetrexed and cisplatin in mesothelioma, multiple trials have been conducted that have further informed management options. Anti‐angiogenesis agents such as bevacizumab and nintedanib appear promising as adjuncts to first‐line chemotherapy. Meanwhile, immunotherapy, anti‐mesothelin agents and molecular targeted therapies are potential areas for development, with ongoing trials promising to deliver interesting results over the next few years. Current evidence does not support surgical intervention; however, investigations are ongoing as to the role of extended pleurectomy/decortication, and surgery in the context of trapped lung. Finally radiotherapy is effective as a palliative measure for pain control, but is not indicated prophylactically to prevent the development of procedure tract metastases.

Read More…

Radiofrequency Ablation Effectively Treated Focal Recurrence of Mesothelioma

Science Direct – June 2018, Pages e265-e267

A 55-year-old man with malignant pleural mesothelioma underwent multimodality treatment comprising induction chemotherapy followed by extrapleural pneumonectomy and radiation therapy. After 2.5 years, focal recurrence occurred, with computed tomography revealing a tumor in the left cardiophrenic angle. Surgery was considered a problem for the patient because of the previous extrapleural pneumonectomy and difficult tumor location. Radiofrequency ablation was therefore performed; the course was uneventful, and there was no recurrence. Radiofrequency ablation should be considered an option to treat recurrence of malignant pleural mesothelioma.

Read More…

A Clinical Trial of TumorGlow to Identify Residual Disease During Mesothelioma Pleurectomy and Decortication

Presented at the Late-Breaking Session of the Fifty-fourth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 27–31, 2018.


Macroscopic complete resection can improve survival in a select group of patients with malignant pleural mesothelioma. During resection, differentiating residual tumor from inflammation or scar can be challenging. This trial evaluated near-infrared (NIR) intraoperative imaging using TumorGlow (a novel NIR imaging approach utilizing high-dose indocyanine green and delayed imaging) technology to improve detection of macroscopic residual disease.


Twenty subjects were enrolled in an open-label clinical trial of NIR intraoperative imaging with TumorGlow (Indocyanine Green for Solid Tumors [NCT02280954]). Twenty-four hours before pleural biopsy or pleurectomy and decortication (P/D), patients received intravenous indocyanine green. All specimens identified during standard-of-care surgical resection and with NIR imaging underwent histopathologic profiling and correlative microscopic fluorescent tomographic evaluation. For subjects undergoing P/D (n = 13), the hemithorax was evaluated with NIR imaging during P/D to assess for residual disease. When possible, additional fluorescent lesions were resected.


Of 203 resected specimens submitted for evaluation, indocyanine green accumulated within 113 of 113 of resected mesothelioma specimens, with a mean signal-to-background fluorescence ratio of 3.1 (SD, 2.2 to 4.8). The mean signal-to-background fluorescence ratio of benign tissues was 2.2 (SD, 1.4 to 2.4), which was significantly lower than in malignant specimens (p = 0.001). NIR imaging identified occult macroscopic residual disease in 10 of 13 subjects. A median of 5.6 resectable residual deposits per patient (range, 0 to 11 deposits per patient), with a mean size of 0.3 cm (range, 0.1 to 1.5 cm), were identified.

Read More…

Mesothelioma News Article Archive Continued…

Mesothelioma Claims: Mesothelioma Damages

If you’ve received a diagnosis of Mesothelioma, it’s crucial to understand that you may be eligible to seek compensation for a wide range of damages. This guide will help you navigate the complex world of Mesothelioma claims, offering insights into the various types of damages you may be entitled to recover. From Mesothelioma-specific damages to economic, medical, and even punitive damages, we’ll break down what each entails, ensuring you have the knowledge you need when considering legal action. Your journey to seeking rightful compensation starts here.

Disfigurement Damages (past and future)
Economic Damages (past and future)
End of Life Cost Damages
Exemplary Damages
Funeral Expense Damages
Future Economic Damages
General Damages
Gross Negligence Damages
Loss of Companionship
Loss of Consortium Damages
Loss of Earning Capacity Damages
Loss of Life Damages
Loss of Wages Damages (past and future)
Medical Expense Damages
Mental Anguish Damages
Monetary Compensation Damages
Nominal Damages
Non-Economic Damages
Pain and Suffering Damages
Pecuniary and Non-Pecuniary Damages
Physical Impairment Damages (past and future)
Punitive Damages
Treble Damages
Workers Compensation Damages
Wrongful Death Claims


When confronted with the devastating impact of a mesothelioma diagnosis resulting from asbestos exposure, pursuing legal action becomes a crucial step towards securing the compensation you rightly deserve. Our team is here to assist you in initiating a mesothelioma lawsuit with an experienced mesothelioma attorney, ensuring the protection of your rights and the delivery of justice. Discover today which Asbestos Trust Funds you may be eligible for to receive compensation.


Scheduling a free case consultation is your first step toward seeking justice in mesothelioma cancer lawsuits. We are ready to assess your unique situation and provide the guidance you will need during this challenging time. Take this essential step toward pursuing fair compensation for your mesothelioma-related injuries.


When dealing with the complexities of mesothelioma cancer lawsuits, getting help from an experienced injury attorney is crucial. For more than 24 years, we have assisted workers, veterans, and families in obtaining the compensation they deserved from negligent asbestos companies. Contact us at 888.640.0914 to secure the support you will need throughout your pursuit of fair and just compensation.

24 Hour Call Back Guarantee!

Mesothelioma Lawsuit Damages - Mesothelioma Research NewsFill out our free Mesothelioma case evaluation form and an experienced Mesothelioma lawyer will call you to immediately start processing your claim at no cost to you.

Call Today! 888.640.0914 – Chat Available 24/7 – 365 Days a Year!

Call Today!

Mesothelioma Damages: Mesothelioma Research News